All Articles
Longevity

How Telomir Pharmaceuticals Is Proving Breakthrough Longevity Science Through Dogs

September 30, 2024
x min read
How Telomir Pharmaceuticals Is Proving Breakthrough Longevity Science Through Dogs

Telomir Pharmaceuticals is aiming to develop a breakthrough in human longevity science through a new drug. And they’re seeing compelling validation that it might work from an initial test in dogs.

What’s happening:

  • Telomir Pharmaceuticals (NASDAQ: TELO) has been making potential breakthroughs in developing new therapeutics for human longevity through the pre-clinical advancement of their novel drug Telomir-1

The big idea:

  • Telomeres are a region of repetitive DNA sequences at the end of a chromosome and ultimately protect the ends of chromosomes from becoming damaged or frayed
  • Telomeres are particularly important during cell division as they allow cells to divide without losing genes
  • However, telomeres tend to shorten as human beings age which reduces their ability to protect chromosomes and can ultimately increase the likelihood of age related and degenerative diseases forming
  • Telomir Pharmaceuticals novel therapeutic Telomir-1 is aiming to elongate telomeres, sustain self renewal of stem cells and prevent against telomeres shortening as human beings age

Why it matters:

  • Telomir Pharmaceuticals previously saw potential breakthrough validation for Telomir-1 when dosing two different dogs who both had preexisting health challenges, with one dog showing remission from terminal cancer and the other dog regaining full mobility after suffering from severe arthritis

Going deeper:

  • Telomir Pharmaceuticals is specifically targeting age related inflammatory diseases such as osteoarthritis which currently has no effective singular treatment and instead relies on mitigating pain through different medications, therapy and even surgeries
  • Through a collaboration with Italian life sciences company InSilicoTrials, Telomir-1 was previously run through advanced modelling and simulations made possible by artificial intelligence technology to determine that the mechanism of action may be a potent metal inhibitor which could potentially lead to reversing aging through the regeneration of telomeres

The intrigue:

  • The Nobel Assembly at the prestigious Swedish university Karolinska Institute previously awarded the Nobel Prize in Physiology or Medicine to a team of scientific researchers for the discovery of how chromosomes are protected by telomeres

Disclaimer

The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by Telomir Pharmaceuticals for a media campaign, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of Telomir Pharmaceuticals without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.

Discover the world's most disruptive early stage companies with 35,000+ investors.

The markets and trends that matter, made simple.

Join top talent at the world's most respected institutions, companies, and venture capital funds.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.